Taking people in FranceNo phase

@neurIST : Intregrated Biomedical Informatics for the Management of Cerebral Aneurysms

Key facts

Who runs it: University Hospital, Geneva
Where: Nantes, FranceSee the siteAlso in 10 other countries, 21 sites
Trial code: NCT05526352
Status: Recruiting
People taking part: 20,000 people, planned
Started: 1 Jun 2015
Expected to end: 1 Mar 2040
Type of study: Observational, 4 groups
Record updated: 16 January 2026

Who can take part

Age: 18 years and older
Sex: Women and men
Healthy volunteers: Can take part

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

able to provide consent or, in the event that a patient is incapable of providing consent, that a person is legally authorized to do so on behalf of the patient according to legal and ethical requirements of the country where the clinical centre is located; Patients:
must have an angiographically proven intracranial aneurysm (MRA< CTA< DSA accepted).The determination of SAH requires the presence of a subarachnoid haemorrhage be verified on CT or by lumbar puncture; MRA: Magnetic Resonance Angiography CTA: Computed Tomography Angiography DSA: Digital Subtracted Angiography

Who cannot take part

failure of a candidate to contribute clinical data,
refusal to provide informed consent

Where in France

Also in 10 other countries, 21 sites

ICANNantes, FranceContact: Romain BourcierTaking people

About the trial

What the trial wants to find out

The primary aim of the SwissNeuroFoundation AneurysmDataBase Project is to implement information technology based tools to create and use a holistic reference database specific to intracranial aneurysms (IA).

Read full original descriptionShow less

The SwissNeuroFoundation AneurysmDataBase are concerned with generating the data with which to populate this database.

The purpose for populating the database are to:

* Screen for and evaluate markers of risk for intracranial aneurysm formation and aneurysm rupture. Are considered as markers the following: genetics factors, microbiota, environmental factors, congenital factors (ie: cerebrovascular anatomical variants), transcriptomics signature, proteomics signature,shape characteristics, haemodynamics characteristics. * Screen for and evaluate prognostic factors of outcome regarding different management strategies including watchful observation, microsurgical treatment, endovascular treatment or any combination thereof. * Implement and evaluate patient-specific management protocols integrating all available information. * Evaluate the impact of the database and use of tools to improve care, reduce costs, support knowledge discovery and promote new industrial developments.

The 4 groups in the trial

IA Patients
Patients with one or more identified intracranial aneurysm, none of which are believed to have ruptured.
IA + SAH Patients
Patients with one or more identified intracranial aneurysm, at least one of which has been radiologically or surgically determined to have ruptured.
Familiy members
Individuals selected on review of a patient's family tree and contacted by said patient, who agree to be approached for recruitment. In affected families each member will be identified as: proband, affected, unaffected, unknown, or not genetically linked.
Healthy Volunteers
Individuals, accompanying or contacted by a patient, or responding to open advertisement, or randomly selected in a defined population who agree to be approached for recruitment.